Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 91

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 91
---
 transaction or other alternative, (e) terminate any negotiations,
discussions or consideration of, or reject, on behalf of Enfusion, any potential transaction or other alternative, (f) recommend to the Enfusion Board the advisability of entering into documents and agreements with respect to any potential
transaction or other alternative, (g) provide to the Enfusion Board a recommendation as to whether the Enfusion Board should approve or disapprove of any potential transaction or other alternative, (h) monitor for, and take actions to
resolve in accordance with the best interests of Enfusion and Enfusion Stockholders in their capacity as such, any developments or circumstances that would reasonably be expected to pose an actual or potential conflict of interest affecting any
director, officer, agent, employee or stockholder of Enfusion relative to a potential transaction or other alternative, a potential counterparty with respect to a potential transaction or other alternative, and (i) engage the Special
Committee’s own financial and legal advisors in connection with the foregoing. The Enfusion Board further resolved that the Enfusion Board would not approve a strategic transaction without a prior favorable recommendation of such transaction by
the Special Committee.

On August 16, 2024, the Special Committee held its inaugural meeting with representatives of Goodwin and
the General Counsel and Assistant General Counsel of Enfusion in attendance. The Special Committee interviewed law firms, including Dechert LLP (“”), to potentially serve as outside counsel to the Special Committee.

On August 23, 2024, the Special Committee held a meeting with the General Counsel and Assistant General Counsel of Enfusion in
attendance. The Special Committee determined to select Dechert to serve as outside counsel to the Special Committee based on Dechert’s expertise and other qualifications, including knowledge of the industry in which Enfusion operates and
experience advising technology companies and special committees in connection with the review and implementation of strategic alternatives, including strategic transactions.

58

On August 27, 2024, FTV confirmed that, at that time, FTV did not have an interest in
acquiring Enfusion or have an intention to proactively seek a rollover of their shares in a potential transaction and that FTV did not presently regard a rollover to be a condition to supporting a transaction and that FTV would promptly inform
Goodwin if any of these declarations were to change. FTV also confirmed that, unless approved in advance by the Special Committee, FTV would not enter into discussions or negotiations with any potential buyer, nor with ICONIQ